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Abstract
Background: Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional
components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent
discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for
normal brain functioning including attention and other neuropsychological skills.
Materials and methods: In our large observational study we monitored 810 children from 5 to 12 years of age
referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination
with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO®
(further on referred to as the food supplement) is developed on the basis of current nutritional science and
containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective
was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit,
impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was
performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and
acceptance (compliance) of the dietary therapy were documented.
Results: After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as
magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and
hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems
at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep,
decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of
16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%)
and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption
of the food supplement was recommended by the paediatricians for 61.1% of the children.
Conclusion: Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well
as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and
adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety
profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended.
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Fish is brain food, a popular opinion says. Due to its
high amount of polyunsaturated fatty acids (PUFA),
such as omega-3 and omega-6, which are essential for
all mammals, fish consumption is regarded to be advan-
tageous for brain development and function [1,2].
A possible reason is that phospholipids containing
PUFA are integral parts of the neuronal cell membranes
of the brain, and they might be important for facilitating
the transmission of signals between neurons [3].
Furthermore, micronutrient intake, e.g. iron, magnesium
and zinc, has been linked to the development, structure
and function of the brain [4]. Consequently, an emer-
ging literature deals with the relationship between nutri-
tion, attention and executive functions in the
development of children and adolescents [5,6].
Evidence indicates that PUFA may play an important
role in the prevention and treatment of certain mental
health disorders [7,8] like, for example, attention deficit
hyperactivity disorder (ADHD). ADHD is one of the
most common behavioural childhood disorders with
prevalence rates of 5.29% worldwide [9] and 4.8% in
Germany [10]. Several studies have been conducted,
suggesting a link between omega-3/omega-6 fatty acids
on the one hand and ADHD symptoms and learning
difficulties on the other [11]. Trials with supplementa-
tion of a combination of two long-chained omega-3
acids, i.e. eicosapentaenoic acid (EPA) and docosahexae-
noic acid (DHA), in children with reading writing disor-
der (RWD), dyspraxia (i.e., motor coordination
difficulties or developmental coordination disorder), and
ADHD-related symptoms have reported significant
symptom reductions [12-14]. In contrast, trials with
DHA only have been less promising [15,16], suggesting
that the presence of the EPA component might be
important.
The role of micronutrients has been investigated as
well. For example, a study of 48 children [17] suggests
that low zinc levels are correlated with inattentiveness
symptoms in children with ADHD. Another rando-
mized, controlled trial of 608 children found that, over a
14-month period, micronutritient supplementation
improved attention-concentration symptoms in school
children [18]. Nogovitsina and Levitina [19] identified
decreased plasma and erythrocyte magnesium levels and
decreases in Mg(2+)-ATPase activity in children with
ADHD.
However, the role of specific diets or dietary nutrients
in the prevention and management of ADHD is still
questioned [20,21]. A recent review indicates that the
evidence is best for zinc [22]. Moreover, a mono-causal
role for nutrient deficiencies in children with ADHD or
ar o l ef o ras p e c i f i cd i e ti nt h et r e a t m e n to fA D H D
seems to be unlikely. So far, in ADHD guidelines [23]
multimodal treatment is recommended including psycho
education, psychosocial interventions, psychotherapy,
and pharmacotherapy. Recommendations for dietary
nutrients have not yet been implemented. However,
many parents follow general nutritional recommenda-
tions for the intake of PUFAs and nutrients in order to
improve their children’s behavioural problems [24].
Our large observational study focuses on children
whose parents judged them to be prone to inattentive-
ness and hyperactivity and therefore consulted their pae-
diatricians. The paediatricians recommended treatment
with ESPRICO®, a chewable capsule which was devel-
oped on the basis of current nutritional science contain-
ing a combination of omega-3 and omega-6 fatty acids
as well as magnesium and zinc, to support attention.
The percentage of the EPA in relation to DHA is inten-
tionally high, because studies indicate that especially
EPA can effectively improve perception, attention, mem-
ory and mood [13,25-27]. To optimize the benefit for
children with attention problems, the food supplement
also contains the omega-6 fatty acid gamma-linolenic
acid (GLA) and the minerals magnesium and zinc.
By monitoring the children over a period of at least 12
weeks, we evaluated the effects of this dietary measure.
In addition, the influence of ESPRICO® on impulsivity,
hyperactivity, emotional problems, and sleep related
symptoms, as well as the dietary supplement’s safety and
acceptance were investigated.
Methods
Study objective
The primary objective was to evaluate the nutritional
effects of PUFA in combination with magnesium and
zinc in children on the core symptoms of ADHD (inat-
tention, impulsivity/hyperactivity) in a primary care set-
ting. Following a dimensional construct of ADHD, the
primary outcome was assessed dimensionally using stan-
dard ADHD scales. In line with the dimensional
approach, we did not define severity cut-offs for the
ADHD-scale nor did we define a-priori the existence of
a formal ADHD diagnosis. The secondary objective was
to investigate effects on emotional and behavioural pro-
blems as well as on sleep related disturbances in chil-
dren who were referred for such problems. Finally
profiles for tolerability, safety, and compliance were
investigated.
Study design and population
This was an observational, longitudinal study investigat-
ing possible effects of a dietary supplement containing a
combination of omega-3 and omega-6 fatty acids as well
as magnesium and zinc. The intended naturalistic study
population was a sufficient large sample of children in
primary care settings referred for attentional and
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Due to the strictly observational character of the study,
no control group was included. Only children for whom
the food supplement was indicated according to the
clinical judgment of the paediatrician and who received
the dietary supplement for the first time in their life
were eligible for participation in the study. The con-
sumption of the PUFA-magnesium-zinc combination
was based on the clinical recommendation of the physi-
cian. Subject assessment was performed by interviews
using internationally standardized questionnaires (see
below) at baseline, after 2 to 4 weeks (interim interview)
and at the end of the study period of 12 weeks (final
interview). In cases of adverse events additional interim
interviews could be conducted at any time. The final
interview also included assessments of safety and accep-
tance using information provided by physicians and par-
ents. Children suffering from supplement related
allergies (e.g. fish and evening primrose oil and any
ingredients of the food supplement) were excluded from
the study.
Treatment
ESPRICO® is a product that contains a combination of
omega-3 and omega-6 fatty acids as well as magnesium
a n dz i n c( T a b l e1 ) .I ti sa v a ilable as chewable capsules
or sachets of suspension; the recommended daily dose
of is 2 × 2 capsules or 1 sachet of suspension.
Assessment procedures
The assessments were obtained by the participating pae-
diatricians during interviews with the children’s parents.
The data were documented using an electronic case
report form. The following two standardized question-
naires were administered at baseline, after 2 to 4 weeks
(interim interview) and after 12 weeks (final interview):
SNAP IV, assessment of attention deficit, hyperactivity/
impulsivity
The SNAP-IV rating scale is a revised version of a ques-
tionnaire developed by Swanson, Nolan and Pelham
(SNAP) used to measure attention deficit and hyperac-
tivity symptoms [28] strictly following the international
ADHD criteria. The scale contains a total of 30 ques-
tions (items). Because we wanted to investigate the
nutritional effect of PUFA in combination with magne-
sium and zinc on inattention, impulsivity and hyperac-
tivity, only the 18 items summarized by the subscales
for attention deficit (item 1-9) and hyperactivity/impul-
sivity (item 11-19) were used in this investigation. These
18 items also cover the DSM-IV criteria for ADHD [29].
Each of the 18 questions had to be answered on a 4-
point Likert-like scale ranging from 0 ("never or rarely”)
to 3 ("very often”). For both subscales separate item sum
scores are calculated for each child, which then were
added to obtain a total score with a (theoretical) range
between 0 (absence of any symptoms) and 54 (all 18
items at maximum symptom frequency). The changes in
average point scores (APS) between the three interviews
(baseline, interim, final) are expressed as absolute and
relative (percent) change from baseline.
According to the scale’s standardization the majority
of the population of children without ADHD falls within
a total score range of 0 to 5. The maximum level is
never reached in practice. A total score of 20 to 25 is
considered as threshold for an ADHD diagnosis. Regard-
ing the individual subscales, intra-individual APS item
sum scores of 16 (subscale attention deficit; correspond-
ing to a mean score of 1.78) and 13 (subscale hyperac-
tivity/impulsivity; corresponding to a mean score of
1.44), respectively, are cons i d e r e dt ob ei n d i c a t i v eo f
clinically relevant disorders. According to the authors of
the scales these scores indicate the 95
th percentile of the
SNAP-IV validation sample [28].
SDQ - Strengths and Difficulties Questionnaire
According to Goodman et al. the SDQ provides a gen-
eral evaluation of emotional and behavioural problems
[30,31]. The SDQ comprises a total of 25 questions
(items) which are divided into five subscales entitled
Emotional Problems, Behavioural Problems, Hyperactiv-
ity, Problems with Peers, and Pro-social Behaviour. To
minimize compliance problems due to the length of
assessment, 5 items of the SDQ were selected ("many
worries, often seems worried”, “often unhappy; down-
hearted or tearful”, “nervous or clingy in new situations;
easily loses confidence”, “many fears; easily scared”).
These four items were taken from the subscale Emo-
tional Problems whereas the fifths question “rather soli-
tary, tends to play alone” was taken from the subscale
Problems with Peers. Each question was evaluated on a
three-point scale ranging from 0 ("not true”), over 1
("somewhat true”), to 2 ("certainly true”). Furthermore,
the four items taken from subscale Emotional Problems
are summarized by an APS for which absolute and rela-
tive change from baseline are specified.
Evaluation of sleep
Based on information provided by parents and children
throughout the study, the observing paediatricians docu-
mented potential sleep related problems, i.e. problems
Table 1 Content of four capsules of ESPRICO®
(recommended daily dose)
Omega-3 EPA (eicosapentaenoic acid) 400 mg
Omega-3 DHA (docosahexaenoic acid) 40 mg
Omega-6 GLA (gamma-linolenic acid) 60 mg
Magnesium 80 mg (21% of RDA)
Zinc 5 mg (50% of RDA)
RDA: Recommended Daily Allowance.
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impaired sleep quality. Answers were recorded as “yes”
or “no”, and for each item the rate of impairment at the
end of the trial compared to impairment at baseline was
determined.
Data analysis and statistics
The observed data were analyzed descriptively, and all p
values reported below are intended to be descriptive
(values ≤0.05 are considered to be descriptively signifi-
cant). Data management and statistical calculations were
performed using Superbase for Windows 2001 database
software and SPSS for Windows (version 15.0.1) statisti-
cal analysis software. Analyses were performed for the
whole study population as well as for subgroups, i.e. dif-
ferent genders and age groups. All participating children
were included in the analyses.
Results
In total, 139 paediatric practices in Germany partici-
pated in the study recruiting 810 children and adoles-
cents (see table 2), aged 4 to 15 years with nearly
two-thirds (530; 65.4%) between 7 and 10 years. All of
them were treated with the food supplement and were
followed up over a period of at least 12 weeks. Reasons
for recommendation are listed in table 3. The study did
not interfere with any medical procedures including
medication or other therapeutic interventions.
Dropouts
During the study period 113 subjects (14%) discontinued
the intake of ESPRICO® prematurely. Reasons for drop-
out were mainly „absence of a positive effect” (50; 6.2%)
and „lack of compliance” (42; 5.2%). Nine children
(1.1%) did not take ESPRICO® over the whole study per-
iod (12 weeks) because of adverse reactions. More than
96% of the subjects attended all three interviews: the
baseline interview was performed in 810 children
(100%), the interim interview in 781 children (96.4%)
and final interview in 792 children (97.8%).
Concomitant medication
At the start of the study 59 children (7.3%) received
medical treatment. The most frequently listed medica-
tions were drugs for treatment of obstructive pulmonary
diseases (N = 13; 1.6%), psychotropic drugs (N = 9;
1.1%) and thyroid therapeutics (N = 9; 1.1%). The psy-
cho stimulants administered included methylphenidate
(N = 7; 0.9%) and unspecified amphetamines (N = 1;
0.1%). Atomoxetine, the only non-stimulant medication
approved for treatment of ADHD, was given to one
child (N = 1; 0.1%). Four children (0.5%) were under
treatment with the homeopathic complex (ingredients:
chamomile dil., potassium phosphoricum, staphisagria,
valeriana).
Dietary therapy
During study participation the food supplement was
administered for an average (± SD) period of 85 ± 19
days, with a maximum exposure of 156 days. 767 chil-
dren (94.7%) received the recommended dose of 2 × 2
capsules per day (range: 2-8 capsules per day).
Attention deficit
Initially, 308 children (38%) reached clinically relevant
APS assessed by SNAP-IV in the area of attention defi-
cit, i.e. an APS of 16 points or above. 227 (73.7%) of the
children with initially elevated scores remained below
this threshold at the final interview. Taking all subjects
into account, APS for attention deficit showed a signifi-
cant reduction from baseline to the end of the study by
an average of 5.36 points (Table 4), corresponding to a
relative improvement of 33.6% of the baseline score.
The study sample included more than 70% boys
whose attention deficit problems were slightly more pro-
nounced than those of the participating girls. A gender-
specific evaluation also revealed a clear reduction of the
attention deficit symptoms as reflected by APS in boys
and girls during the study period (Figure 1). The
Table 2 Demographic characteristics of study population
Study population (N) 810 (100%)
Male/female 579/231
Age (yr; median) 8.6
Weight (kg; mean) 31.3
Weight (kg; min-max) 13.8-87.2
Height (cm; mean) 134
Height (cm; min-max) 101-178
Existing diseases at baseline (N (%)) 112 (13.8%)
Psychiatric disease at baseline (N (%)) 41 (5.1%)
Concomitant medication at baseline (N (%)) 59 (7.3%)
Dropouts therapy (N (%)) 113 (14%)
Table 3 Reasons for treatment with ESPRICO® (answers
not mutual exclusive)
N%
Lack of concentration 746 92.1
Lack of attentiveness 681 84.1
Aggressive behavior 6 0.7
Agitation/hyperactivity 41 5.1
Enhancement of endurance and productivity 11 1.4
Sleeping disorders 3 0.4
Other indications 21 2.6
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at 5.1 ± 5.2 points for boys and 5.6 ± 5.4 points for girls
(mean ± SD). Sub-analyses of different age groups
showed no clinically significant differences in attention
deficit reduction.
Hyperactivity/Impulsivity
On the SNAP-IV Hyperactivity/Impulsivity subscale 320
children (39.5%) initially had an APS of 13 points or
above and were thus classified to have a clinically rele-
vant disorder in this particular area. At the end of the
study, 202 of these children (63.1%) improved to an
APS below the threshold of 13 points. Altogether, APS
for hyperactivity/impulsivity decreased by at least 3.65
points over the study period (Table 4), corresponding to
a relative improvement of 28.2% of the baseline score.
Results of gender-specific analyses showed a signifi-
cantly higher impairment of boys in this area over the
whole study period. The symptoms for impulsivity/
hyperactivity as mirrored by APS were reduced by
averages of 3.6 ± 5.2 points for boys and by 3.4 ± 4.8
points for girls (Figure 2). Thus, the symptoms were
reduced to a similar degree in both genders in the
course of the study.
Sub-analyses of different age groups showed that chil-
dren between 4 and 6 years of age (N = 155) presented
with significantly higher pre-treatment hyperactivity/impul-
sivity scores than older children (Figure 3). With a mean
value of 4.7 ± 5.9 points this age group also showed the
most pronounced decrease in APS in this study, compared
to decreases by 3.7 ± 4.9 points in 7-10 years old children
and by 2.6 ± 4.4 points in 11-15 years old children.
Emotional and behavioural problems
Between baseline and the final assessment the percentage
of children who were described as loners (completely or
Table 4 Decrease in average point scores (APS) from baseline to the end of the study
N Decrease in points (mean) Standard deviation 95% Confidence interval p*
Attention deficit (APS) 754 5.36 5.23 4.98-5.73 < 0,001
Hyperactivity/impulsivity (APS) 756 3.65 5.11 3.29-4.02 < 0,001
SNAP-IV (total score) 734 8.99 9.02 8.33-9.64 < 0,001
Emotional problems (APS) 781 0.25 0.52 0.21-0.29 < 0.001
* two-sided t-test.
Figure 1 Decrease in average point scores (APS) for attention deficit assessed by SNAP-IV for 551 boys and 225 girls. Mean and 95%
confidence interval.
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Page 5 of 12Figure 2 Decrease in average point scores (APS) for hyperactivity/impulsivity assessed by SNAP-IV for 556 boys and 223 girls.M e a n
and 95% confidence interval.
Figure 3 Reduction of average point scores (APS) for hyperactivity/impulsivity assessed by SNAP-IV in children of different age
groups. Mean and 95% confidence interval (sample size, 4-6 yr: 155; 7-10 yr: 513; 11-15 yr: 111).
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(261 of 810).
Comparing baseline and final interview the summary
score computed as the mean value of the four items
from the SDQ subscale Emotional Problems decreased
significantly by an average of 0.25 ± 0.52 points (Table
4), corresponding to a relative decrease by 28.1% of the
baseline value.
Subgroup analyses of different age groups showed only
slight differences in decrease of the summary score, but
children between 4 and 6 years of age were generally
less affected by emotional problems.
Gender-specific evaluation showed that emotional pro-
blems were more prevalent in girls. Reduction of symp-
toms as reflected by the summary score was similar for
both genders with averages of 0.2 ± 0.5 points in boys
and of 0.3 ± 0.6 points in girls (Figure 4).
Sleep related problems
Information provided by parents and children during
the interviews regarding falling asleep, sleeping through
the night and sleep quality revealed that problems with
falling asleep existed much more frequently than pro-
blems with sleeping through or reduced sleep quality. In
the course of the observational period the percentage of
children with sleep-related problems was reduced signif-
icantly in each of the three areas by more than 40%
(Table 5).
Sub-analyses of different age groups showed only
slight differences, with older children having more pro-
blems to fall asleep. Improvement of sleep related symp-
toms was similar in all age groups.
A gender-specific evaluation revealed that at baseline
girls had more problems with falling asleep (43.2% of n
= 229 vs. 36.3% of n = 567). During the course of the
study this difference disappeared, indicating that with
regard to “falling asleep” girls drew more benefit from
taking ESPRICO® than boys (Figure 5).
Assessment of safety and tolerability
At the final interview tolerability and safety of the food
supplement was assessed by the investigators and the
parents of the participating children. The observing phy-
sicians assessed the tolerability of PUFA in combination
with magnesium and zinc to be very good or good in
711 children (87.8%), moderate in 45 children (5.6%),
and poor in 11 children (1.4%). Likewise, the parents
rated the tolerability as very good or good in 82.9% of
the children, as moderate in 73 children (9.0%), and as
poor in 20 children (2.5%). At the end of the study per-
iod the observers recommended continuation of intake
in 495 (61.1%) of the participating children.
Adverse events
A total of 31 adverse events (AEs) were reported by 24
children (3.0% of 810) during the observational period
of 12 weeks. All AEs were considered by the
Figure 4 Decrease in average point scores (APS) for emotional problems assessed by SDQ for 577 boys and 231 girls. Mean and 95%
confidence interval.
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serious adverse event (SAE) occurred. According to the
investigators, 16 AEs reported by 14 children (1.7%) had
a possible, probable or confirmed causal relationship to
the intake of the food supplement. The most frequently
reported AEs were reactions of the gastrointestinal tract,
e.g. nausea or vomiting, and psychiatric disorders (Table
6). Nine children (1.1%) discontinued the intake of the
dietary supplement in the context of an intolerance
reaction. All patients experiencing AEs recovered with-
out sequels.
Assessment of acceptance
At the final interview the acceptance of ESPRICO® con-
sumption was assessed by the parents (Table 7). Accord-
ing to these ratings ESPRICO® was always, or at least
usually, taken willingly by 526 children (64.9%). A total
of 60 children (7.4%) refused to take the dietary supple-
ment at least occasionally. An analysis of different age
groups revealed that children between 4 and 7 years of
age refused (always or sometimes) much more often (21
of 153; 13.8%) than older children (39 of 612; 6.4%).
Discussion
ADHD and Emotions
Most subjects showed a substantial reduction in symp-
toms of attention deficit and hyperactivity/impulsivity as
well as of emotional and behavioural problems. These
findings are in line with many other studies reporting a
positive effect of PUFA on ADHD symptoms [32-35].
Also micronutrients like magnesium [36,37] and particu-
l a r l yz i n ch a v ep r o v e dt ob ei m p o r t a n tw i t hr e g a r dt o
treatment of ADHD [22,38] and improvement of ADHD
related symptoms [39,40].
Sleep
Sleeping disorders, mainly problems to fall asleep,
decreased significantly during the 12 week consumption
of PUFA in combination with magnesium and zinc, with
girls having more benefit than boys and older children
Table 5 Number (%) of children with sleeping disorders.
N Baseline Final interview Decrease in % (95% Confidence interval) p*
Problems to fall asleep 796 305 (38,3%) 182 (22,9%) 40.3 (28.1-50.6) < 0,001
Problems to sleep through the night 797 148 (18,6%) 87 (10,9%) 41.2 (22.9-55.4) < 0,001
Reduced sleep quality 784 186 (23,7%) 107 (13,6%) 42.4 (26.6-55.1) < 0,001
* two-sided chi-square test.
Figure 5 Percentage of children with problems to fall asleep at the three different interviews. Boys: 567; girls: 229.
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could be related to emotional problems, which are
known to be correlated with sleep problems: The calmer
and more balanced a person is, the better the sleep
quality; the better the sleep quality, the better daytime
attention and concentration will be. This inter-relation
is probably also the reason for the gender-specific differ-
ences: Girls showed higher SDQ-scores for emotional
problems over the whole study period and accordingly
they had more problems to fall asleep; the same expla-
nation applies for older children. An underlying bio-
chemical mode of action involves the polyunsaturated
fatty acids (PUFA), which are structural and functional
components of cell membranes and pre-stages of the
hormonally and immunologically active eicosanoids.
These eicosanoids play an important role in neural func-
tion, including sleep induction via prostaglandin D2
[41]. Lavialle et al. [42] fed hamsters a PUFA-deficient
diet and found a 52% reduction in the nocturnal peak
level of melatonin compared to control hamsters (P =
0.001). In accordance with Scheer and Czeisler [43] they
conclude that a PUFA-deficient diet may play a role in
nocturnal sleep disturbances via melatonin release also
in humans.
Tolerability
Overall, the safety profile of the food supplement is
characterized by a low rate of side effects. The partici-
pating children or their parents reported neither severe
nor serious adverse events, and the majority of poten-
tially related events subsided spontaneously. A total of
16 adverse events with a possible causal relationship to
the study medication were reported by 14 children
(1.7%). Nine children (1.1%) discontinued the study
because of incompatibility reactions. Most frequently,
subjects experienced reactions of the gastrointestinal
tract (Table 6), e.g. nausea or vomiting, which can be
considered as common intolerance reactions to prepara-
tions containing fish oils [32]. Nausea and burps are
also common after a regular fish meal [44]. To our
knowledge there are no reports of any serious reactions
after consumption of PUFA. A study using nutritional
supplements comparable to this specified combination
of PUFA, magnesium and zinc did not find any physio-
logically relevant changes (blood cell count, liver
enzymes) in the verum group, too [45].
Acceptance
Acceptance problems with consumption of the food
supplement occurred rarely. However, a total of 60 chil-
dren (7.4%) did not take the supplement at least occa-
sionally and only 42 children (5.2%) discontinued
participation in the study due to acceptance problems.
Thus, this nutritional supplement was accepted by a
large majority of the study population ensuring a suffi-
cient level of compliance.
Limitations
This observational, longitudinal study is subject to the
limitations applying to this type of study in general. For
this reason, the level of evidence is lower as compared
with randomized controlled trials or with case-control
studies. Due to the lack of a control group and no con-
trol of treatment allocation, multiple confounding can-
n o tb er u l e do u t .H o w e v e r ,d u et ot h el a r g en u m b e ro f
participants and the longitudinal design, this study can
Table 6 Adverse events classified by the observers to
have a possible, probable or confirmed causal
relationship to the consumption of ESPRICO® (MedDRA
System Organ Classes and Preferred Terms)
N%
Infections and parasitic diseases 1 0.1
Infection 1 0.1
Psychiatric diseases 5 0.6
Difficulty sleeping through the night 1 0.1
Restlessness 1 0.1
Sleep-related problems 2 0.2
Behavioural disorder 1 0.1
Diseases of the gastrointestinal tract 8 1.0
Abdominal symptoms 1 0.1
Distended abdomen 1 0.1
Abdominal pain 2 0.2
Dyspepsia 1 0.1
Nausea 1 0.1
Vomiting 2 0.2
Diseases of the skin and hypodermis 1 0.1
Urticaria 1 0.1
Injury, intoxication and complications resulting from
interventional procedures
1 0.1
Nausea in connection with a procedure 1 0.1
Children with no adverse reactions 796 98.3
Children, total 810 100
Table 7 Acceptance of ESPRICO® according to the parents
Children ... N %
... always took it willingly 226 27.9%
... usually took it willingly 300 37.0%
... sometimes took it only after “verbal encouragement” 179 22.1%
... sometimes refused 44 5.4%
... always refused 16 2.0%
No information 45 5.6%
Total 810 100%
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several limitations have to be addressed: The validity of
t h ec o m p l i a n c er e p o r t si sl i m i t e ds i n c ed a t ac o u l dn o t
be cross-validated by pill counts or other methods of
compliance control. Therefore compliance may have
been overestimated. Furthermore, the study situation
itself may have contributed to increased attention paid
to the children during the observational period, influen-
cing the outcome of the study. Also we did not control
for socioeconomic status, which might influences effec-
tiveness [39]. Additionally, comparisons with other
effectiveness studies are limited by methodology, e.g., by
differences in the scales used as outcome measures. Elig-
ibility for participation was based on the presence of
symptoms of inattention and behavioural problems
rather than on a confirmed ADHD diagnosis and co-
morbidities. Nevertheless, to date this is the largest
observational study in this area, assessing more than 800
subjects in a longitudinal design.
Conclusion
Due to the common nutritional practices in industria-
lized western countries, with high amounts of processed
food products containing mostly very low levels of long-
chained omega-3 fatty acids (DHA and EPA), one can
expect a discrepancy between desirable and actual intake
of these long-chained omega-3 fatty acids in both adults
and children. But DHA and EPA can also be synthesized
from alpha-linolenic acid (ALA), an omega-3 fatty acid,
in the liver through a series of elongation and de-satura-
tion steps. ALA itself occurs in a number of green vege-
tables as well as in certain nuts and seeds. However,
there have been recent concerns that the efficiency of
the conversion process may be low because both
omega-3 and omega-6 fatty acids share and compete for
the same enzymes that are used for de-saturation and
elongation [46]. Omega-6 fatty acids, such as linoleic
acid (LA) and arachidonic acid (AA), are widely present
in vegetable oils, seeds, nuts, margarine, grains, eggs,
and meats, whereas PUFAs are found primarily in
canola and soybean oil, flaxs e e d ,w a l n u t s ,e g g s ,s o m e
meats, and cold water fish (2). Highest concentrations of
DHA and EPA are found only in very few fatty cold
water fish, e.g., salmon, mackerel and herring. Thus,
intake of omega-6 fatty acids is much higher than that
of omega-3 fatty acids which may be associated with an
increased risk of mental health disorders [7,47] and
other diseases like arteriosclerosis [48].
New strategies for improving this poor dietary situa-
tion in the general population are needed considering
the fact that fish stocks are limited and that mercury
poisoning might be dangerous when eating high
amounts of cold water fish (mainly shark, swordfish,
king mackerel, tuna and tilefish). Various authorities
have already given adequate recommendations. They
include food supplements such as fish oil capsules or
functional foods like microencapsulated omega-3 fatty
acid products. For example, eggs, yogurt, milk, and
spreads have been enriched with these fatty acids [44].
Taking both the essential nutritional role of omega-3
fatty acids EPA and DHA on attention and concentra-
tion in children [overviews in [6] and [49]] and the
favourable risk-benefit ratio of the preparation into
account, the results of this study support a recommen-
dation of the use of PUFA in combination with magne-
sium and zinc in children. Similar suggestions for
supplementation of PUFA have been made before [50].
With regard to children diagnosed to suffer from
ADHD this study may be of heuristic importance, but it
cannot establish a proof of efficacy due to its methodo-
logical limitations. However, taking concerns of the par-
ents, teachers and patients regarding stimulant
treatment into account, it is important to propel insights
into innovative approaches to help children and adoles-
cents with ADHD. PUFA do not necessarily contradict
the therapy; however, if efficacy can be proven by con-
trolled studies, it may serve as a primary and supportive
approach. Adequate dosage of PUFA for ADHD-patients
needs to be examined for they seem to have a different
fatty acid metabolism [C51, 52].
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